Detalles del proyecto
| Estado | Activo |
|---|---|
| Fecha de inicio/Fecha fin | 1/13/23 → 10/25/26 |
Financiación
- Merck Sharp & Dohme Corporation: 166.877,00 US$
22-LUN-130-MSD (MK-7339 -013-03): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Conc
- Hao, Zhonglin (PI)
- Zinner, Ralph (Former PI)